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Abstract
Background: Cushing’s Syndrome (CS) which is caused by isolated Corticotropin-releasing hormone (CRH)
production, rather than adrenocorticotropin (ACTH) production, is extremely rare.
Methods: We describe the clinical presentation, course, laboratory values and pathologic findings of a patient with
isolated ectopic CRH causing CS. We review the literature of the types of tumors associated with this unusual
syndrome and the behavior of these tumors by endocrine testing.
Results: A 56 year old woman presented with clinical and laboratory features consistent with ACTH-dependent CS.
Pituitary imaging was normal and cortisol did not suppress with a high dose dexamethasone test, consistent with
a diagnosis of ectopic ACTH. CT imaging did not reveal any discrete lung lesions but there were mediastinal and
abdominal lymphadenopathy and multiple liver lesions suspicious for metastatic disease. Laboratory testing was
positive for elevated serum carcinoembryonic antigen and the neuroendocrine marker chromogranin A. Serum
markers of carcinoid, medullary thyroid carcinoma, and pheochromocytoma were in the normal range. Because the
primary tumor could not be identified by imaging, biopsy of the presumed metastatic liver lesions was performed.
Immunohistochemistry was consistent with a neuroendocrine tumor, specifically small cell carcinoma.
Immunostaining for ACTH was negative but was strongly positive for CRH and laboratory testing revealed a plasma
CRH of 10 pg/ml (normal 0 to 10 pg/ml) which should have been suppressed in the presence of high cortisol.
Conclusions: This case illustrates the importance of considering the ectopic production of CRH in the differential
diagnosis for presentations of ACTH-dependent Cushing’s Syndrome.
Introduction
Cushing’s syndrome (CS) comprises the clinical manifes-
tations of exposure to elevated glucocorticoid hormones,
either from exogenous sources or endogenous overpro-
duction by the adrenal glands [1]. CS from endogenous
production is rare with an incidence of 0.7 to 2.5 per mil-
lion per year depending on the geographic region and
population studied [2]. Although autonomous cortical
adrenal adenomas or carcinomas are a cause of elevated
cortisol, most cases (85 to 90%) are adrenocorticotropic
hormone (ACTH) dependent and are caused by cortico-
troph pituitary adenomas (Cushing’s Disease or CD) [1].
The remaining ACTH-dependent cases mostly involve
non-pituitary malignancies( E c t o p i cA C T H )w h i c ho f t e n
are tumors of neuroendocrine origin such as small cell
lung carcinoma or bronchial carcinoid [3,4]. Here, we
d e s c r i b eac a s eo fC u s h i n g ’s syndrome which initially
appeared to be caused by ectopic ACTH secretion from
metastatic small cell carcinoma. However, immunohisto-
chemistry of the tumor cells was negative for ACTH
expression, while corticotrophin releasing hormone
(CRH) was strongly expressed, suggesting that the ele-
vated ACTH levels were a result of pituitary secretion in
response to CRH.
Case report
A 56 year old type 2 diabetic patient presented to the
emergency room with shortness of breath. Review of
systems revealed back pain for two weeks, without
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and fatigue for many months. She also described con-
stant right upper quadrant abdominal pain. On exami-
nation, there was hyperpigmentation of her face and
neck in sun exposed areas, thin skin with violacious
striae on her lower abdomen, and multiple ecchymoses
over the extremities, abdomen and at venipuncture sites.
There was prominent fat accumulation in the supracla-
vicular and dorsocervical regions. There also was objec-
tive evidence of proximal muscle weakness which, along
with back pain, had caused her to be bed-ridden for two
weeks. Her medications included an oral sulfonylurea
for diabetes but no exogenous sources of corticosteroids.
Laboratory results revealed hypokalemic alkalosis (K
+
2.1 mEq/l and HCO3 42 mEq/l). She was hyperglycemic
(random glucose 339 mg/dl). An MRI of the spine
showed multiple endplate compression fractures of the
thoracic and lumbar vertebrae.
A clinical diagnosis of CS was suggested by the pre-
sentation. The laboratory results are summarized in
Table 1. Morning serum cortisol was extremely elevated
and did not suppress after 1 mg Dexamethasone. The
urinary cortisol was 16,575 μg/24 hours (normal 0-
50 μg), which was confirmed on dilution. ACTH was
elevated (278 pg/ml) in spite of hypercortisolism, con-
firming ACTH-dependent CS. A 48 hour high dose dex-
amethasone suppression test (2 mg every 6 hours for 8
doses) did not cause suppression of the serum cortisol
suggesting that this was a case of ectopic ACTH and, in
agreement, the pituitary gland had a normal appearance
on MRI. Computed tomography (CT) of the chest did
not reveal any lung nodules but did show mediastinal
lymphadenopathy. CT abdomen showed multiple lesions
in the liver and enlarged para-aortic and retroperitoneal
lymph nodes suggestive of metastatic disease. The adre-
nal glands were prominent but were without focal
nodularity.
Because no primary lesion was found on imaging, a
number of follow-up laboratory tests were performed.
Chromogranin A and Carcinoembryonic antigen (CEA)
were elevated consistent with a malignancy with neu-
roendocrine characteristics (Table 1). Laboratory tests
for known causes of ectopic ACTH-namely, carcinoid
(serotonin, 24 hour urine 5-hydroxy-indoleacteic acid),
pheochromocytoma (plasma free metanephrines and
normetanephrines), and medullary thyroid carcinoma
(calcitonin)- were in the normal range (Table 1). Gastrin
was over 2-fold higher than the upper limit of normal.
With the exception of the liver metastases and
enlarged lymph nodes, there were no discrete lung
nodules or neck, abdomen or pelvis lesions seen on CT.
Scintigraphy with [
111-In]pentreotide showed no tracer
uptake at 4 hours. Specimens from bronchoalveolar
lavage did not show any histologic findings of small cell
lung carcinoma.
The patient’s course continued to deteriorate, with
hypokalemia, hyperglycemia and difficult to control
blood pressure. She was started on ketoconazole, an
Table 1 Laboratory Presentation
AT PRESENTATION (Normal Range) VALUE
Serum Potassium (3.8-5.2 mEq/l) 2.1
Serum HCO3 (21-32 mEq/l) 42
Plasma Glucose (mg/dl) 339
Morning Serum Cortisol (06:15) (4.0-32 μg/dl) 111.1
ENDOCRINE WORK-UP (Normal Range)
1 mg Overnight Dexamethasone Supression Test (Normal cortisol < 1.8 μg/dl) 116.7
48 hour High Dose Dexamethasone Supression Test (Normal cortisol < 1.8 μg/dl) 109.8
24 hour Urine Free Cortisol (0 to 50 μg) 16 575
Plasma ACTH (10-46 pg/ml) 278
Plasma CRH
a (0-10 pg/ml) 10
Plasma Chromogranin A (0-5.0 nmol/l) 26
Serum Carcinoembryonic antigen (0-5.0 ng/ml) 10.59
Serum Calcitonin (0-5 pg/ml) < 2.0
Serum Serotonin (0-420 ng/ml) 156
Plasma Metanephrine (0-62 pg/ml) and
Normetanephrine (0-145 pg/ml)
12
37
Serum Gastrin (13.0-115.0 pg/ml) 280
24 hr Urinary 5-HIAA (0-8.0 mg) 6.7
Abbreviations: ACTH, Adrenocorticotropic Hormone; CRH, Corticotropin Releasing Hormone, 5-HIAA, 5-hydroxy-indoleacetic acid
aCRH assay is a plasma based test by which Corticotropin Releasing Factor is measured by direct radioimmunoassay (Inter Science Institute, Inglewood, CA).
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continued to escape inhibition after each dose escalation
(Figure 1). The patient then was switched to metyra-
pone, resulting in a significant decrease in cortisol levels
(Figure 1). Chemotherapy was initiated (cisplatin and
vincristine) but the patient become hemodynamically
unstable after one round of therapy and was transferred
to the intensive care unit where she passed away. An
autopsy was declined by the family which prevented
confirmation of the origin of the small cell carcinoma.
Pathological findings
CT guided biopsy of one of the liver lesions was per-
formed to obtain tissue for diagnosis. The biopsy con-
sisted of multiple cores of soft tissue with no liver
parenchyma present, although rare glandular structures
were seen, suggestive of the residual bile ducts in the
portal triad. On hematoxylin and eosin staining, there
was extensive infiltration by small blue tumor cells sur-
rounded by slender fibrous tissue (Figure 2). The cells
were discohesive with small nucleoli, powdery chroma-
tin, and no observable cytoplasm. The tumor cells were
positive for neuroendocrine markers chromogranin, and
synaptophysin as well as CD56 and Thyroid Transcrip-
tion Factor-1 (TTF-1) (Figure 2). The cells were negative
for the epithelial markers pancytokeratin and LC8
(CD45). These histopathologic findings were suggestive
of small cell carcinoma. Surprisingly, immunostaining
was negative for ACTH (Figure 2) (rabbit polyclonal
antibody from Cell Marque, 1:200 dilution). Because of
this, immunostaining for CRH was performed (rabbit
polyclonal antibody from Sigma-Aldrich at a 1:200 dilu-
tion) which was strongly positive (Figure 2). Subse-
quently, a laboratory test for plasma CRH revealed that
it was 10 pg/ml, at the upper limit of normal (0-10 pg/
ml), in spite of concurrent hypercortisolism (Table 1).
Discussion
Cushing’s syndrome (CS) is the clinical manifestations of
cortisol overproduction from ACTH-independent (adre-
nal cortical adenoma or carcinoma) or ACTH-dependent
mechanisms. Most ACTH-dependent CS is due to corti-
cotroph pituitary adenomas (90%), while ectopic ACTH
production only comprises around 10% of cases [4].
A significant proportion of ACTH-secreting neoplasms
(7-19%) remain occult even after extensive investigation
[4-6]. There have been few reports of ACTH producing
tumors which co-secrete CRH and even fewer which
describe ectopic CRH production in the absence of
ACTH, as we suspect in this case. Overall, an extensive
search of the literature revealed isolated CRH reported in
20 cases [7-17]. Medullary thyroid carcinoma (33%) and
pheochromocytoma (19%) are the most prevalent among
the cases of isolated ectopic-CRH, while carcinoid (5%)
and small cell lung carcinoma (9.5%) are less common,
different from ectopic ACTH cases, with the latter two as
the most prevalent causes (Table 2)[7-17]. Interestingly,
isolated CRH production from prostate cancer comprises
14% of the cases [9,14] and yet it is an extremely rare
source of ectopic ACTH (1-3%).There are single reports
of sellar choristoma and gangliocytoma with isolated
CRH production [9,14].
We believe our patient had a CRH secreting tumor
due to strongly positive CRH staining, negative ACTH
staining, and detectable plasma CRH. A simple explana-
tion for the lack of ACTH immunostaining is that it is
not expressed in the tumor cells. The polyclonal anti-
body used for our ACTH immunostaining also reacts
with the parent propeptide, pro-opiomelanocortin, so
that aberrant prohormone processing of POMC to
ACTH is not an explanation. We have not examined
whether POMC transcripts were present in the biopsy
sample, but there is precedence that POMC RNA can
be present without detectable pro-peptide or ACTH in
the tissue [7,18]. In these cases, it is not clear whether
the POMC transcripts are not properly translated, or
the ACTH is secreted too soon after production to be
stored [9]. In our patient, we only biopsied the meta-
static lesions in the liver, so that we also cannot rule
out that other non-hepatic metastatic lesions were able
to produce ACTH.
An interesting aspect of this case is the lack of signifi-
cant cortisol suppression by the high dose dexametha-
sone suppression test (HDDST; 2 mg dexamethasone
every 6 hours for 48 hours), with baseline cortisol at
122.2 μg/dl before the test and 109 μg/dl after 48 hours.
With isolated ectopic CRH, it is expected that CS devel-
ops through the stimulation of pituitary ACTH secretion
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Figure 1 Plasma cortisol levels during the patient’sh o s p i t a l
course and treatment. a = ketoconazole 200 mg PO BID,
b= ketoconazole 400 mg BID, c= ketoconazole 400mg TID,
d= metyrapone 500 mg QID.
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this, ACTH and cortisol levels potentially could sup-
press with HDDST, similar to a pituitary adenoma.
Young and colleagues [19] reported this false positive
suppression in a case of ectopic CRH-ACTH produc-
tion, which also behaved like Cushing’sd i s e a s eb yC R H
stimulation testing and inferior petrosal sinus sampling
(IPSS). However, in the case presented here as well as
that of seven other ectopic CRH cases, the lack of sup-
pression of ACTH and cortisol are consistent ectopic
ACTH production, avoiding the superfluous perfor-
mance of other, sometimes invasive, pituitary-centered
procedures (e.g. IPSS) [3]. Similarly, a single dose of 8
mg dexamethasone (overnight) has not suppressed corti-
sol in cases of isolated ectopic CRH [12,17]. These find-
ings confirm that the positive drive by CRH can
overwhelm the negative feedback by elevated corticos-
teroid. The systemic CRH levels in the case reported
here were at the upper end of normal. Most other pub-
lished cases of ectopic CRH reports do not have the
CRH levels available for comparison.
Conclusion
We present a rare case of isolated ectopic CRH produc-
tion from metastatic small cell carcinoma of unknown
primary. From the literature, the tumors most commonly
associated with ectopic CRH production are medullary
Figure 2 Immunohistochemistry of biopsy samples from a CT guided biopsy of a liver metastasis. The cells stained positively for
chromogranin, synaptophysin, thyroid transcription factor 1 (TTF-1) and CD-56. The cells stained negatively for ACTH but were strongly positive
for CRH.
Table 2 CRH Positive and ACTH negative Tumors causing
Cushing’s Syndrome
NEOPLASM % of CASES (n =
21)
REFERENCES
Medullary Thyroid Cancer 33 [8,9,11,15,18]
Pheochromocytoma 19 [10,11,13,16]
Prostate Cancer 14 [9,17]
Small Cell Lung Carcinoma 9.5 [14,17]
Small Cell Carcinoma (occult
primary)
1
9.5 [14]
Carcinoid 5 [14]
Other < 10 [14,9]
1 Including the case presented here.
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cancer. With ectopic CRH syndrome, it is assumed that
the pituitary is the source of ACTH with secretion driven
by CRH overproduction. However, these tumors have
behavior distinct from pituitary corticotroph adenomas,
and the majority appears to lack suppression with high
dose dexamethasone. Although the clinical presentation
may be similar to ectopic ACTH syndrome, it is impor-
tant to have ectopic CRH syndrome in the differential
diagnosis for Cushing’s syndrome.
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